US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Healthcare & Pharmaceuticalscategory· March 21, 2025 Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market Eli Lilly launched its blockbuster diabetes and ...

Investing.com -- Novo Nordisk 's (NYSE:NVO) (CSE:NOVOb) blockbuster weight-loss drug Wegovy may have difficulty securing approval from Medicare for coverage as a heart disease... In a recent ...

The strong growth was driven by the increased sales volume of Mounjaro and Zepbound. The company’s quarterly earnings per share more than doubled, rising 114% to $5.32 per share. Eli Lilly and ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).